The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ANKSILON (Orion Pharma (AUS) Pty Limited)
Product name
ANKSILON
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
135 (255 working days)
Active ingredients
buspirone hydrochloride
Registration type
New generic medicine
Indication
ANKSILON (buspirone hydrochloride) is indicated for the short-term treatment of anxiety. The ordinary anxiety and tension associated with the stress of everyday life usually does not require treatment with an anxiolytic agent.